Table 2

Summary of direct meta-analysis for all-cause mortality and adverse event outcomes

InterventionStudies (n)Active intervention*Control (placebo unless otherwise noted)*
No. with eventTotal (n)No. with eventTotal (n)OR (95% CI)
All-cause mortality
 Full-dose thrombolysis162310104210060.64 (0.37 to 1.09)
 Low-dose thrombolysis11613600.32 (0.03 to 3.13)
 Catheter-directed thrombolysis10301290.31 (0.01 to 7.96)
 Full-dose thrombolysis versus low-dose thrombolysis4411271861.04 (0.24 to 4.41)
Major bleeding
 Full-dose thrombolysis169910103810062.39 (1.44 to 3.95)
 Low-dose thrombolysis1061060Not estimable
 Catheter-directed thrombolysis1030029Not estimable
 Full-dose thrombolysis versus low-dose thrombolysis4911271862.26 (0.78 to 6.58)
Intracranial haemorrhage
 Full-dose thrombolysis14
2
1598329783.66 (1.13 to 11.86)
 Low-dose thrombolysis1061060Not estimable
 Catheter-directed thrombolysis1030029Not estimable
 Full-dose thrombolysis versus low-dose thrombolysis339701616.85 (0.74 to 63.24)
Recurrent VTE
 Full-dose thrombolysis1119945379450.57 (0.32 to 1.03)
 Low-dose thrombolysis10613600.13 (0.01 to 2.64)
 Catheter-directed thrombolysis1030029Not estimable
 Full-dose thrombolysis versus low-dose thrombolysis349761611.35 (0.36 to 5.00)
  • *Patients also received standard anticoagulation.

  • VTE, venous thromboembolism.